Screener
Climb Bio, Inc. CLYM Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210357
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease liabilities | 263 | 256 |
| Total current liabilities | 4,071 | 6,984 |
| Operating lease liabilities, net of current portion | 216 | 285 |
| Total liabilities | 4,287 | 7,269 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value; 250,000,000 shares authorized; 47,768,543 and 47,766,338 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 5 | 5 |
| Additional paid-in capital | 451,372 | 449,762 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Climb Bio, Inc.'s total liabilities?
- Climb Bio, Inc. (CLYM) reported total liabilities of $4.29M in Q1 2026.
- How has Climb Bio, Inc.'s total liabilities changed year-over-year?
- Climb Bio, Inc.'s total liabilities decreased by 41.7% year-over-year, from $7.36M to $4.29M.
- What is the long-term trend for Climb Bio, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Climb Bio, Inc.'s total liabilities has grown at a 18.9% compound annual growth rate (CAGR), from $3.06M to $7.27M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Climb Bio, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude